

Current Perspective on Vitamin D Deficiency: A Mini Review

Aarti Sood Mahajan*, Prerana Agarwal*

Abstract

Vitamin D deficiency is a very common global problem today. Children, pregnant mothers, young adults and the elderly, all are at risk. This is an unexpected revelation since it is presumed that people in countries with abundant sunshine would have adequate levels of the vitamin. Various socio-cultural practices are responsible for this scenario. The decrease in vitamin D levels could be due to diet, lifestyle or disease. This mini review brings out the causes of vitamin D deficiency, regional and global scenario of the problem, as well as physiological and clinical conditions associated with the variation in the vitamin levels. Various clinical disorders where the deficiency has been documented, and possible mechanism suggested by different authors have been highlighted, with the aim to encourage in-depth reading. An attempt is made to reinforce to every doctor, the importance of vitamin D deficiency and how this awareness may be useful to them to understand various symptoms experienced by patients and to modulate their treatment protocols of various clinical disorders.

J Physiol Biomed Sci. 2017; 30(1): 5-11

Keywords: Vitamin D deficiency, physiological variations.

Introduction

Vitamin D has gained recognition, acceptability, and shifted its role from a vitamin to a hormone of varied importance. Although many countries have abundant sunshine, there is still vitamin D deficiency in most parts of the world and in most age groups. This could be due to reduced synthesis, decreased absorption and increased catabolism. This mini review is an attempt to reinforce the importance of vitamin D to every physician, and to make them aware that cases they see every day may be accompanied by a latent or preclinical levels of vitamin D deficiency which, when also treated, can further improve the patient's health.

A Global Problem

The problem is global with reports from Asia, Europe, Latin America, Africa and America.¹ In north and south Europe, values of vitamin D reported were 40-50 nmol/l and 20-30 nmol/l, respectively. The higher values in the northern region irrespective of unfavorable latitude were related to the consumption of fatty fish, cod liver oil and more sun seeking behaviour.² In a systemic literature review, it was found that the highest 25-hydroxyvitamin D [25(OH)D] values were observed in North America.³ Age-related differences were observed in Asia Pacific and Middle East/Africa regions. No sex-related

differences were observed. In a historical perspective written by Holick and Chan, the measures taken by different countries and their consequences have been mentioned.⁴

The South-East Asian Scenario

Recent reviews have highlighted that deficiency exists even in South-East Asian countries. Data from China, South Korea and Thailand have been mentioned.^{5,6} A reported deficiency of 70-100% in otherwise healthy individuals has been reported in India. The prevalence of deficiency is 86% in less than 3 months old, 61% in 2-60 months age group and 53.35% in postmenopausal women. Deficiency exists in both sexes and in both rural and urban population. Awareness, clothing, vegetarian food preferences, and unaffordable supplements are some causes mentioned in various studies. Twenty to forty five minutes of sun exposure may be required for adequate synthesis of vitamin D and, surprisingly, this also is not obtained in day-to-day activities.⁷⁻¹¹

Normal Values of Vitamin D, And Its Deficiency

Serum 25(OH)D, available from sunlight and dietary sources with a half-life of 3-4 weeks, being the circulating and storage form, serves as the best available indicator of vitamin D status of the body. Serum levels of 1,25-dihydroxycholecalciferol, the active metabolite of vitamin D, is subject to variations, secondary to changes in parathyroid hormone levels of the body. The US Institute of Medicine defines serum 25(OH)D levels of >50 nmol/l as sufficient, 30-50 nmol/l as inadequate and <30 nmol/l as deficiency.¹² Similarly, WHO refers to

*Department of Physiology, Maulana Azad Medical College, Bahadur Shah Zafar Marg, New Delhi 110002, India.

Corresponding author: Dr Aarti Sood Mahajan
E-mail: aarti_mahajan@yahoo.co.in

Received 29 January 2017, Accepted 7 November 2017

© 2017 Journal of Physiological and Biomedical Sciences
Available online at www.j-pbs.org

<50 nmol/l as insufficiency.¹³ The Endocrine Society Task Force defines vitamin D deficiency as a serum 25(OH)D concentration below 20 ng/ml (<50 nmol/l) and an optimum level being 30-50 ng/ml for maximum effects of vitamin D on calcium, bone and muscle metabolism.¹⁴ Deficiency may be classified according to the levels of 25(OH)D (in ng/ml) as severe deficiency <5, deficiency <15, insufficiency 15-20, sufficient 20-100, excess (hypervitaminosis) >100, and intoxication >150.¹⁵ For comparison of values, different units are mentioned, but 1 nmol/l is equivalent to 0.4 ng/ml.

Requirement and Sources of Vitamin D

The adequate intake, or estimated average requirement, of infants, 1-18 years old, pregnant and lactating women is 400 IU/d. A daily supplementation of 400 IU under situation of minimal exposure to sunshine is recommended by the Indian Council of Medical Research. The upper limit is 1,000 IU/d for 0-6 months old, 1,500 for 6-12 months old, 2,500 for 1-3 years old, 3,000 for 4-8 years old, 4,000 for 9 years old and above, pregnant and lactating mothers. A US study suggests recommended daily allowance for women and children as 600 IU/d.¹⁶⁻¹⁹ The two forms of vitamin D may have different sources: ergocalciferol (vitamin D₂) is formed in plants and yeast; cholecalciferol (vitamin D₃), is synthesized in skin and obtained from animal dietary sources. Sunlight, diet, supplements, and prescription drugs are the major sources when there is a state of deficiency. The various sources of vitamin D are listed in Table 1. It is recommended that vitamin D should be obtained from a healthy diet and not unprotected exposure to UV radiations.²⁰⁻²²

Metabolism of Vitamin D

The precursor of vitamin D₃ (7-dehydrocholesterol) is found in the epidermis. Ultraviolet ray exposure (280-320 nm) converts it to a previtamin. Its cis form then converts to vitamin D₃ (cholecalciferol) by a thermal non-enzymatic process. In the bloodstream its half-life is 36-78 h. It is then taken up by adipocytes in subcutaneous and omental fats. When vitamin D₃ and D₂ are acted upon by an enzyme 25-hydroxylase of the cytochrome P450 enzyme system, it gets converted to 25(OH)D or calcidiol, whose half-life is 21-30 days. This is further converted into 1,25-dihydroxy vitamin D [1,25(OH)₂D] by 1 α -hydroxylase in the proximal convoluted tubule of kidney. This enzyme is also present in extra renal sites like prostate, breast, colon, keratinocytes, and monocytes. Locally produced 1,25(OH)₂D is under autonomous endocrine control. 1,25(OH)₂D inversely regulates its own concentration by inducing synthesis of the enzyme, 25-hydroxyvitamin D-24-hydroxylase, and is converted into an inactive water soluble metabolite calcitroic acid. 24-Hydroxylase also acts

Table 1 Sources of vitamin D (natural sources, food and therapeutic drugs)²⁰⁻²²

Sunlight	Fish, mackerel, tuna, salmon
UV light	Milk, yogurt, cheese
Artificial lamps	Vitamin D ₂ ergocalciferol (capsule)
Human breast milk	Vitamin D ₂ ergocalciferol liquid
Cod liver oil	(injection)
Egg yolk	Vitamin D ₃ calcitrol
Mushroom	Vitamin D ₃ calcitrol liquid
Cereal	Multivitamin
Orange juice	Vitamin D ₃ cholecalciferol

on 25(OH)D forming inactive 24,25(OH)₂D.²²⁻²⁵

Mechanism of action

A steroid hormone, 1,25(OH)₂D links with vitamin D receptor (VDR), binds to a retinoic acid X receptor, and forms a heterodimer. This binds to promoter regions of target genes and modifies transcription. VDR also interacts with other transcription factors like co-activator proteins, transcription integrators like calcium-binding proteins, and transcriptional apparatus like steroid receptor activator complex (SRC). Vitamin D regulates some 200-2000 genes involved in many processes, like cell proliferation, differentiation, and apoptosis; synthesis of bactericidal proteins; immunomodulation; and angiogenesis. Its levels are influenced by parathyroid hormone (PTH) activity. This raises the calcium levels in the body by increasing its absorption from intestine, resorption from the bone and decreased excretion from the kidneys.^{26,27}

Physiological Factors Affecting Vitamin D Levels

Sunlight, lipids, enzymes and various host factors contribute to a normal level of vitamin D. An exposure to sun rays to bare face, arms, and legs, for about 45 minutes daily, is adequate for normal synthesis of vitamin D.¹¹ Some factors which cause its deficiency are endemic to regions and populations; others arise from rapidly changing lifestyles, industrialization and urbanization. Table 2 gives a list of such factors. These are responsible for deficiency and must be kept in mind while calculating therapeutic dose and duration of therapy.^{2,4,11,19,20,22,24,28-36}

Clinical Disorders Associated With Vitamin D Deficiency

Suddenly, increased awareness and research make us feel there is a vitamin D deficiency epidemic. However most cases of vitamin D deficiency are asymptomatic and remain undetected until deficiency becomes severe and prolonged. Classically, vitamin D deficiency presents as metabolic bone disease, as rickets in children and as osteomalacia in adults, with or without accompanying hypocalcemia and tetany. Bones become demineralized and softened, epiphyses of long bones become enlarged, and there is growth

Table 2 Physiological variations in vitamin D levels and proposed mechanisms

Factors	Vit. D levels	Mechanisms
Genetics, migrants from Asia, Africa compared to non-Hispanic white ^{2,28}	variable	Genetic traits; vitamin D receptor genotypes; cultural behavior
Athletes ³¹	variable	Insufficient UV ray exposure, indoor sports, early morning or late evening training, sunscreen use
Old age ^{4,30}	↓	Decreased dehydrocholesterol concentration
Ozone ²²	↓	Blocks sunlight
Pollutants ²²	↓	Absorb, scatter, or reflect rays
Latitude below 35° N ²	↑	More sunlight
Clothes (wool, silk, nylon, polyester); sunscreen; cultural beliefs, keeping skin covered ²²	↓	Block sunlight
Indoor staying, crowded areas, elderly, disability, hospitalized ²	↓	Less exposure to sunlight
Melanin ²²	↓	Block sunlight
Adiposity, obesity ³⁴	↓	Concentration of vitamin in large amount of adipose tissue
Scar/burn ³⁵	↓	Blocks sunlight
Dietary practices, boiling, calcium deficient, rich in phytate, lactose intolerance ¹¹	↓	Less availability
Pregnant mothers ^{19,29}	↓	More requirement
Postmenopausal symptoms, vaginal atrophy, urinary incontinence, cardiovascular ³⁶	↓	Urothelium, smooth muscle of detrusor has vitamin D receptor. Other associated problems
Breast fed infants ³³	↓	Indoors, availability and metabolism
Poor sleep quality ³²	↓	Time spent indoors, less physical activity
Drugs: phenobarbitone, phenytoin, carbamazepine, rifampicin, isoniazid, antiretroviral, glucocorticoids ^{20,33}	↓	More catabolism

retardation, bone discomfort and muscle aches, lower back pain, leg deformities and stress fractures. Older women may have proximal muscle weakness, frequent falls, and heaviness in legs, chronic musculoskeletal pain and fatigue.^{1,3,4,37-40} The role of vitamin D in several nonosseous diseases is being documented as shown in Table 3.^{22,35,41-72} However we should be cautious while associating each disease with vitamin D deficiency, because in some conditions like schizophrenia its importance is doubtful.⁷³

Treatment of Vitamin D Deficiency

Exposure to sunlight and artificial UVB radiation

Controlled, sensible exposure of skin to sunlight /UVB, arms and legs alone to sunlight, for 5-30 minutes between 10 am and 3 pm, two to three times per week, synthesizes enough vitamin D in skin to prevent its deficiency. Although skin pigmentation does not affect the amount of sunlight reaching, but the duration of exposure required may vary, being more in dark skinned individuals. The concerns with UVB exposure, both, natural and artificial, are those of sunburn, skin aging, melanoma and non-melanoma skin cancers.

Vitamin D supplementation

Both vitamin D₃ (cholecalciferol) and vitamin D₂, (ergocalciferol) are available as prescription drugs and as oral dietary supplements. Doses for treatment are 2000 IU/d or 50,000 IU once a week for 6 weeks

(infant to 18 years of age), and for adults, 6000 IU/d or 50,000 IU/once a week for 8 weeks. Maintenance dose of 400 IU/d is given to infants, 600 IU/d for 1-18 years old and 1500-2000 IU/d for adults. Similarly a higher dose of vitamin D is needed in older, obese patients with mild to moderate hepatic failure and intestinal fat malabsorption syndrome. The dose response curve shows that a supply from 20 µg (800 IU/d) to 500 µg (20,000 IU/d) will maintain serum levels of 25(OH)D within a range of 75-220 nmol/l by homeostatic control mechanisms.^{74,75}

Calcium supplementation

In children, especially on stoss therapy with vitamin D, calcium supplementation 30-75 mg/kg/d in three divided doses for 1-2 weeks as a preparation of either citrate, carbonate, gluconate, or lactate may be needed until parathyroid and vitamin D levels normalize.³³ This aids remineralization, and prevents hypocalcemia and hungry bone syndrome. Thereafter, the dose may be reduced.

Monitoring

It is recommended that after one month of initiating therapy, serum calcium, phosphorous, and alkaline phosphate levels are measured. After 3 months, these along with serum magnesium, vitamin D and PTH levels may be estimated. Repeated investigations should be done if there is no clinical improvement or if otherwise required. Calcium and phosphorous levels are the earliest to normalize, within 6-10 days. Serum vitamin D and PTH levels take 1-2 months,

Table 3 Proposed mechanism linking insufficient vitamin D levels to clinical conditions

Disease/Disorder	Mechanism of vitamin D abnormality or improvement with therapy
Rickets, osteoporosis, fractures, fall in elderly, joint/back pains ^{41,42}	Alterations in bone metabolism and calcium levels
Rheumatoid arthritis ⁴³	TNF- α activity not suppressed; increased IL-6, IL-10, CRP and inflammatory markers
Decreased testosterone, estrogen, FSH, LH levels ^{44,45}	Influencing testosterone-to-estrogen conversion by aromatase
GI diseases: celiac, Crohn, pancreatitis, cystic fibrosis, liver failure, gastric bypass	Decreasing absorption of oral intake
Inflammatory bowel disease ²²	Preventing suppression of Th-1 cell response in inflammation
Kidney disease ²²	Phosphate retention and loss of function inhibit 25(OH)D-1 α hydroxylase.
Hypertension, stroke, atherosclerosis ^{46,47}	Vitamin D treatment decreases renin and arterial stiffness, improves vascular dysfunction, reduces oxidative stress. Higher incidence of cardiovascular events and mortality
Diabetes, hyperlipidemia, metabolic syndrome ⁴⁸	With therapy, insulin resistance decreases and insulin sensitivity increases. Statin therapy associated with lower vitamin D levels
Preeclampsia, impaired glucose intolerance ⁴⁹	Increasing chances of cesarean section; deficit in bone mineral accrual in children up to 9 years; low birth weight of offspring
Infertility ⁵⁰	Treatment improves cell survival and sperm motility, PCOS, IVF outcome by steroid genesis of sex hormones, placental development and tolerance
Congenital rickets, neonatal hypocalcemic seizure, low birth weight, tooth decay, fractures, childhood immune disorders ^{35, 51}	Maternal 25(OH)D and vitamin D-binding protein might regulate expression of placental amino acid transporter.
Autism ⁵²	Decreased tryptophan hydroxylase (TPH)1; increased TPH2 (brain); decreased serotonin
Influenza, asthma, bronchiolitis ⁵³	Seasonal deficiency; vitamin D treatment enhances innate immune response
Tuberculosis ^{54,55}	Vitamin D upregulates antimicrobial peptides, cathelicidin.
HIV ^{56,57}	Vitamin D supplementation reduces HIV transmission and comorbidity.
Depression ^{58,59} , dementia ⁶⁰ , Alzheimer ⁶¹ , Parkinsonism ⁶²	Vitamin D therapy improves symptoms.
Multiple sclerosis ⁶³	Severity of disease decreases with vitamin D therapy.
Lupus erythematosus ⁶⁴	Reducing memory B cells and effector T cells; increasing regulatory T cell
Psoriasis, atopic dermatitis, vitiligo, ichthyosis, skin cancer ^{55,66}	Modulating markers of epidermal proliferation; suppressing inflammatory response; enhancing antimicrobial activity; promoting integrity of permeability barrier
Malignancies: epithelial, breast, prostate, non-small cell, colonic, pancreatic, ovarian, non-Hodgkin lymphoma ⁶⁷⁻⁷⁰	Increasing calcium which protects integrity of intercellular junction; decreasing angiogenesis; producing cathelicidin; reducing proliferation
Susceptibility to severe infection and mortality of critically ill ⁷¹	Apoptosis Cancer cells enhance 25(OH)D-1-hydroxylase expression, affecting 1,25(OH) ₂ D levels.
Hyperparathyroidism ⁷²	Treatment decreases mortality. Increasing catabolism of 25(OH)D

and serum alkaline phosphatase levels correct in about 3-6 months. Radiological improvement can be appreciated within 4 weeks.³³

Contraindications to vitamin D therapy

Hypervitaminosis, hypersensitivity and toxicity are absolute contraindications and they must be clearly understood. The liver is able to hydroxylate vitamin D but chronic liver disease and nephrotic syndrome may decrease vitamin D-binding protein. Vitamin D hypersensitivity syndromes occur when extra renal production of 1,25(OH)₂D causes hypercalcemia. This may be seen in some granulomatous diseases like tuberculosis and sarcoidosis, and some cancers e.g. non-Hodgkin's lymphoma and oat cell carcinoma of the lungs. In skin conditions like porphyrias, albinism, xeroderma pigmentosum, skin cancers like melanoma, when there is intake of photosensitizing drugs like tetracycline, phenothiazines, sulfonamides, or psoralens, UV vitamin D therapy is avoided.

Hypercalcemia, hypercalciuria, nephrocalcinosis are results of overdosage. Various symptoms associated with toxicity have to be treated.^{22,26,76}

Future Scope and A Word of Caution

Research has progressed to the extent that it has been reported that newborns have lower cord vitamin D levels if their mother had a low vitamin D level. Roles in placental tolerance, development, fetal imprinting, fetal programming and epigenetic modification are being talked about.¹ Awareness, screening of at risk individuals, diagnosis, treatment and food fortification is required today.⁷⁷ Over-enthusiastic, uncontrolled treatment, overdose, and commercialization of knowledge without proper understanding are to be avoided. Nevertheless increased identification of vitamin D deficiency in the sunny countries of the world is a cause of concern and has to be addressed.^{78,79}

Conclusion

A Pandora box of information has opened, showing us the status of vitamin D, its role in the manifestation of diseases and therapy. All practicing doctors must use this information, read more, and aim to eradicate this deficiency and prevent it from becoming a pan epidemic of modern society.

Acknowledgments

We wish to acknowledge the work of authors mentioned and many others who have contributed to the knowledge of vitamin D.

Conflict of Interest

None.

References

- Hosseini-nezhad A, Holick MF. Vitamin D for health. *A Global perspective.* *Mayo Clin Proc.* 2013; 88(7): 720-55.
- Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. *Osteoporos Int.* 2009; doi:10.1007/S00198-009-0954-6.
- Hilger J, Friedel A, Herr R, et al. A systematic review of vitamin D status in population worldwide. *Br J Nutrition.* 2013; doi:10.1017/S0007114513001840.
- Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. *Am J Clin Nutr.* 2008; 87(suppl): 1080S-6S.
- Nimitphong H, Holick MF. Vitamin D status and sun exposure in South East Asia. *Dermato-Endocrinology.* 2013; 5(1): 34-7.
- Edwards MH, Cole ZA, Harvey NC, Cooper C. The Global epidemiology of vitamin D status. *J Aging Res Clin Practice.* 2014; 3(3): 148-58.
- Mehlawat U, Singh P, Pande S. Current status of vitamin D deficiency in India. *IPP2014;* 2(2):328-35.
- Reshma R, Anitha D. Evaluation of vitamin D status in apparently healthy women above 20 years of age attending a tertiary care hospital. *World J Pharmacy and Pharmaceutical Sci.* 2016; 5(4): 1494-504.
- Tandon VR, Sharma S, Mahajan S, et al. Prevalence of vitamin D deficiency amongst Indian postmenopausal women and its correlation with diabetes; A first cross sectional data. *J Midlife. Health.* 2014; 5(3): 121-5.
- Harinarayan CV, Joshi SR. Vitamin D status in India – Its implications and remedial measures. *JAPI.* 2009(57); 40-8.
- Ritu G, Gupta A. Vitamin D deficiency in India: Prevalence, causalities and interventions. *Nutrients.* 2014; 6: 729-75.
- Institute of medicine (US). Standing committee on the scientific evaluation of dietary references intake calcium, phosphorous, magnesium, vitamin D and fluoride. Washington DC. National Academic press. (US), 1997, 7, vitamin D. <https://www.ncbi.nlm.nih.gov/books/NBK109831>.
- Spiro A, Buttriss JL. Vitamin D: An overview of vitamin D status and intake in Europe. *Nutrition Bulletin.* 2014(39); 322-50. doi:10.1111/mbu.12108.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. *Journal Clin Endocrinol Metab.* 2011; 96(7): 1911-30.
- Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D deficiency in children and its management: Review of current knowledge and recommendations. *Pediatrics.* 2008; 122: 398-417.
- Nutrient requirements and recommended dietary allowances for Indians. A draft report of the expert group of ICMR 2009; <http://icmr.nic.in/final/RDA-2010.pdf>
- Ross AC, Taylor CL, Yaktine AL, Del Vall HB. Dietary reference intake for calcium and vitamin D. Institute of Medicine (US), committee to review dietary reference intake for vitamin D and calcium. The national Academic press, Washington DC, 2011; doi:10.17226/13050. <https://www.ncbi.nlm.nih.gov/books/NBK56070>
- Rathi N, Rathi A. Vitamin D and child health in the 21st century. *Indian Pediatrics.* 2011; 48: 619-25.
- Paxton GA, Teale GR, Nowson CA, et al. Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement. *MJA.* 2013; 198(3): 1-8.
- Bordelon P, Ghetu MV, Langan R. Recognition and Management of vitamin D deficiency. *Am Fam Physician.* 2009; 80(8): 841-6.
- Holick MF. Vitamin D deficiency. *N Engl J Med.* 2007; 357(3): 266-81.
- Tsiaras WG, Weinstock MA. Factors influencing vitamin D status. *Acta Derm Venereol.* 2011; 91: 115-24.
- Vanchinathan V, Lim HW. A dermatologist's perspective on vitamin D. *Mayo Clin Proc.* 2012; 87(4): 372-80.
- Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. *Expert Opin Pharmacother.* 2008; 9(1): 1-12.
- Gröber U, Spitz J, Reichrath J, Kisters K, Holick MF. Vitamin D. *Dermato-Endocrinology.* 2013 (5:3); 331-347. doi:10.4161/derm.26738.
- Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. *Alt Med Rev* 2008; 13(1): 6-20.
- Hausler MR, Whitfield GK, Kaneko I, et al. Molecular mechanisms of vitamin D action. *Calcif Tissue Int.* 2012; doi:10.1007/s00223-012-9619-0.
- Spector TD, Keen RW, Arden NK, et al. Influence of vitamin D receptor genotype on bone mineral density in postmenopausal women: A twin study in Britain. *BMJ.* 1995; 310: 1357.
- Javaid MK, Crozier SR, Harvey NC, et al. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: A longitudinal study. *Lancet* 2006; 367: 36-43.
- Zaidi S. Power of vitamin D. *New Scientific research links vitamin D deficiency to cancer, heart disease, Diabetes, high blood pressure, kidney disease, fibromyalgia, chronic fatigue, osteoporosis,*

- arthritis, lupus, multiple sclerosis, asthma, thyroid disease, dental problems and depression. Digital editions USA, 2012.
31. Larson-Meyer DE, Willis KS. Vitamin D and athletes. *Curr Sports Med Rep*. 2010; 9(4): 220-6.
 32. Gominak SC, Stumpf WE. The world epidemic of sleep disorders is linked to vitamin D deficiency. *Med Hypotheses*. 2012; 79(2): 132-5.
 33. Balasubramanian S, Dhanalakshmi K, Amperayani S. Vitamin D deficiency in childhood – A review of current guidelines on diagnosis and management. *Indian Pediatr*. 2013; 50: 669-75.
 34. Cipriani C, Pepe J, Piemonte S, Colangelo L, Cilli M, Minisola S. Vitamin D and its relationship with obesity and muscle. *Int J Endocrinol*. 2014; 2014: Article ID 841248. doi:10.1155/2014/841248.
 35. Martineau A, Jolliffe D. Vitamin D and human health: From the gamete to the grave. Report on a meeting held at Queen Mary University of London, 23-25 April 2014. *Nutrients* 2014; 6: 2759-2919.
 36. Matyjaszek-Matuszek B, Lenart-lipinska M, Wozinakowska E. Clinical implications of vitamin D deficiency. *Prz Menopauzalny* 2015; 14(2): 75-81. doi:105114/pm.2015.52149.
 37. Kulie T, Groff A, Redmer J, Hounshell J, Schragger S. Vitamin D: An evidence-based review. *J Am Board Fam Med*. 2009; 22: 698-706.
 38. Peterlick M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. *European J Clin Invest*. 2005; 35: 290-304.
 39. Hanley DA, Cranney A, Jones G, et al. Vitamin D in adult health and disease: A review and guideline statement from osteoporosis Canada. *CMAJ*. 2010; 182(12): E610-8. doi:10.1503/cmaj.080663.
 40. Heath RM, Elovic EP. Vitamin D deficiency. Implications in the rehabilitation settings. *Am J Phys Med Rehabil*. 2006; 85(11): 916-23.
 41. Chlebowski RT, Johnson KC, Lane D, et al. 25-Hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women. *Maturitas*. 2011(68): 73-8.
 42. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: A meta-analysis of randomized controlled trials. *BMJ*. 2009; 339: b3692. doi:10.1136/bmj.b3692.
 43. Kostoglou-Athanassiou I, Athanassiou P, Lyraki A, Raftakis I, Antoniadis C. Vitamin D and rheumatoid arthritis. *Ther Adv Endocrinol Metab*. 2012; 3(6): 181-7.
 44. Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. *Endocrinol*. 2000; 141(4): 1317-24.
 45. Wehr E, Pilz S, Boehm BO, Marz W, Obermayer-pietsch B. Association of vitamin D status with serum androgen levels in men. *Clin Endocrinol*. 2010; 73(2): 243-8.
 46. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Caol P. 1,25dihydroxy vitamin D(3) is a negative endocrine regulator of renin angiotensin system. *J Clin Invest*. 2002; 110(2): 229-38.
 47. Weng S, Sprague JE, Oh J, et al. Vitamin D induces high blood pressure and accelerates atherosclerosis in mice. *PLOS One*. 2013; 8(1): doi:10.1371/journal.pone.0054625.
 48. Talaei A, Mohamadi M, Adgi Z. The effect of vitamin D on insulin resistance in patients with type 2 diabetes. *Diabetol Metab Syndr* 2013, 5: 8. Available from <http://www.dmsjournal.com/content/5/1/8>.
 49. De Regil LM, Palacios C, Lombardo LK, Pene Rosas JP. Vitamin D supplementation during pregnancy. *Cochrane Database of Systematic Reviews*. 2016; issue 1. Art No: CD008873. doi:10.1002/14651858.CD008873. pub3.
 50. Lerchbaum E, Obermayer-Pietsch B. Vitamin D and fertility: A systematic review. *Eur J Endocrinol*. 2012; 166(5): 765-78.
 51. Royal College of Obstetricians and Gynecologists. Vitamin D in pregnancy. *Scientific Impact Paper No. 43*. 2014. <https://www.rcog.org.uk-Sip43>.
 52. Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. *FASEB J*. 2014; 28(6): 2398-413.
 53. Rajabbik MH, Lotfi T, Alkhaled L, et al. Association between low vitamin D levels and the diagnosis of asthma in children: A systematic review of cohort studies. *Allergy Asthma Clin Immunol*. 2014; 10: 31.
 54. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: A systematic review and meta-analysis. *Int J Epidemiol*. 2008; 37: 113-9.
 55. Chocano-Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. *Nutrition Reviews* 2009; 67(5): 289-93.
 56. Childs K, Welz T, Samarawickrama A, Post FA. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. *AIDS* 2012; 26: 253-62.
 57. Haug C, Muller F, Aukrust P, Froland SS. Subnormal serum concentration of 1,25 vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. *J Infect Dis*. 1994; 169(4): 889-93.
 58. Li G, Mbuagbaw L, Samaan Z, et al. Efficacy of vitamin D supplementation in depression in adults: A systematic review protocol. *Syst Rev*. 2013; 2: 64. <http://www.systematicreviewsjournal.com/content/2/1/64>.
 59. Anglin RES, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. *Br J Psychiatry* 2013; 202: 100-7. doi: 10.1192/bjp.bp.111.106666.
 60. Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. *Neurology*. 2014; 83: 920-8.
 61. Annweiler C, Llewellyn DJ, Beauchet O. Low serum vitamin D concentration in Alzheimer's disease: A systematic review and meta-analysis. *J Alzheimers Dis*. 2013; 33(3): 659-74.
 62. Evatt ML, DeLong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin D deficiency in patients with Parkinson disease and Alzheimer disease. *Arch Neurol*. 2008; 65(10):1348-52.

63. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. *Neurology*. 2004; 62(1): 60-5.
64. Terrier B, Derian N, Schoindre Y, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. *Arthritis Res Ther*. 2012; 14(5): R221. doi: 10.1186/ar4060.
65. Perez A, Chen TC, Turner A, et al. Efficacy and safety of topical calcitriol (1,25 dihydroxy vitamin d 3) for treatment of psoriasis. *Br J Dermatol*. 1996; 134: 238-46.
66. Wadhwa B, Relhan V, Goel K, Kochhar AM, Garg VK. Vitamin D and skin diseases. A review. *Indian J Dermatol Venerol Leprol*. 2015; 81: 344-55.
67. Grant WB. A critical review of vitamin D and cancer. A report of the IARC Working Group. *Dermatoendocrinol*. 2009; 1(1): 25-33.
68. Holick MF. Vitamin D and sunlight: Strategies for cancer prevention and other health benefits. *Clin J Am Soc Nephrol*. 2008; 3: 1548-54.
69. Garland CF, Mohr SB, Gorham ED, Grant WB, Garland FC. Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. *Am J Prev Med*. 2006; 31(6): 512-4.
70. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Vitamin D intake and risk for pancreatic cancer in two cohort studies. *Cancer Epidemiol Biomarkers Prev*. 2006; 15(9): 1688-95.
71. de Haan K, Groeneveld ABJ, de Geus HRH, Egal M, Strujs SA. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. *Crit Care*. 2014; 18: 660. Available from <http://ccforum.com/content/18/6/660>.
72. Mikhail N. Clinical significance of vitamin D deficiency in primary hyperparathyroidism and safety of vitamin D therapy. *South Med J*. 2011; 104(1): 29-53.
73. McGrath JJ, Burne TH, Feron F, Mackay-Sim A, Eyles DW. Developmental vitamin D deficiency and risk of schizophrenia: A 10 year update. *Schizophr Bull*. 2010; 36(6):1073-8.
74. Tangpricha V, Khazai NB. Vitamin D deficiency and related disorders. <http://emedicine.medscape.com/article/128762-overview>.
75. Vieth R. Vitamin D supplementation, 25-hydroxy-vitamin D concentrations, and safety. *Am J Clin Nutr*. 1999; 69: 842-56.
76. Ozkan B, Hatun S, Bereket A. Vitamin D intoxication. *Turk J Pediatr*. 2012; 54: 93-8.
77. Cranney A, Weiler HA, O'Donnell S, Puil L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. *Am J Clin Nutr*. 2008; 88(suppl): 513S-9S.
78. Smith G, Wimalwansa SJ, Lailou A, et al. High prevalence of vitamin D deficiency in Cambodian women. A common deficiency in a sunny country. *Nutrients*. 2016; 8(5): 290. doi:10.3390/nu/8050290.
79. Bi X, Tey SL, Leong C, Quek R, Henry CJ. Prevalence of vitamin D deficiency in Singapore: Its implications to cardiovascular risk factors. *PLOS One*. 2016; 11(1): e0147616. doi:10.1371/journal.pone.0147616.